Clinical trials: Anlotinib
Esophageal Squamous Cell Carcinoma
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
To evaluate the efficacy and safety of paclitaxel and DDP combined with Anlotinib in the treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04063683
- Testing
- Anlotinib Hydrochloride, Paclitaxel, cisplatin
- Where
- 6 sites in China
- Volunteers
- 47 people
- Sponsor
- Henan Cancer Hospital
Advanced Solid Tumor
Anlotinib in Advanced Solid Tumors With FGFR Alteration
This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.
- Trial name
- NCT03929965
- Testing
- Anlotinib
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Small Cell Lung Cancer
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
- Trial name
- NCT06951841
- Testing
- Liposome Irinotecan, Platinum, Tislelizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- China Medical University, China
Solid Tumor, Adult, Soft Tissue Sarcoma
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in combination with Opdivo (nivilumab) for the treatment patients with of metastatic, advanced, or recurrent solid tumors.
- Conditions
- Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04165330
- Testing
- AL3818, Nivolumab Injection
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study.
- Trial name
- OASIS (NCT04503967)
- Testing
- Anlotinib Hydrochloride With Nivolumab
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital
Limited Stage Small Cell Lung Cancer
This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer
A total of 66 patients were enrolled in this exploratory study and randomly assigned to cohort 1 and cohort 2, with 33 patients in each group.
- Trial name
- NCT06978153
- Testing
- benmelstobart combined with chemotherapy and anlotinib, benmelstobart combined with chemotherapy
- Volunteers
- 66 people
- Sponsor
- Tang-Du Hospital
Hepatocellular Carcinoma
Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
This clinical study evaluates the efficacy and safety of anlotinib in patients with hepatocellular carcinoma who have progressed on lenvatinib treatment.
- Trial name
- ALTER-H-002 (NCT04080154)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
Anlotinib, RCC
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT02072031
- Testing
- Anlotinib, Sunitinib maleate
- Where
- 15 sites in China
- Volunteers
- 133 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
Anlotinib is a multi-target receptor tyrosine kinase inhibitor under domestic research and development. It can inhibit angiogenesis-related kinases, such as VEGFR, FGFR, PDGFR and tumor cell proliferation related kinase c-Kit…
- Trial name
- NCT04619537
- Testing
- Anlotinib Hydrochloride plus Docetaxel
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shandong Cancer Hospital and Institute
NSCLC
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
The Single-arm, multicenter study evaluate the safety and efficacy of Anlotinib Hydrochloride combined with EGFR TKIs in treating Advanced NSCLC With acquired Resistance to EGFR TKIs
- Trial name
- NCT04007835
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangdong Association of Clinical Trials
Advanced Thyroid Cancer Patients Who Received Target Therapy
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer.
- Trial name
- NCT06195228
- Testing
- dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
- Where
- 8 sites in China
- Volunteers
- 800 people
- Sponsor
- Fudan University
Glioblastoma
Newly Diagnosed Glioblastoma
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma.Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness
- Trial name
- NCT04959500
- Testing
- Anlotinib Hydrochloride, Radiation Therapy, Temozolomide
- Where
- 22 sites in China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Colo-rectal Cancer
Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer
Patients with pretreated advanced colorectal cancer are recruited to the phase I portion of this prospective non-randomised study in an escalated dose cohort.
- Trial name
- NCT03545711
- Testing
- Anlotinib Hydrochloride with Irinotecan
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chinese Academy of Medical Sciences
Lung Cancer, Nonsmall Cell
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced non-small cell lung cancer (NSCLC).
- Trial name
- FL-ALTER (NCT04028778)
- Testing
- Gefitinib, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Sun Yat-sen University
Rhabdomyosarcoma Recurrent, Maintenance Treatment
Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children
This is a randomized controlled phase II clinical study aimed at evaluating the efficacy and safety of anlotinib hydrochloride in children with Intermediate-High -risk rhabdomyosarcoma.
- Trial name
- ALTER-02 (NCT07137884)
- Testing
- Anlotinib+Cyclophosphamide+Vinorelbine, Cyclophosphamide+Vinorelbine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Small Cell Lung Cancer Extensive Stage
A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)
This retrospective real-world study aims to evaluate the efficacy and safety of anlotinib hydrochloride combined with immunotherapy as maintenance therapy following standard chemoimmunotherapy in extensive-stage small cell lung…
- Trial name
- NCT06982287
- Volunteers
- 100 people
- Sponsor
- Yong Fang
EGFR Gene Mutation
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
A single arm study: EGFR-TKIs Combine With Anlotinib as First-line Treatment in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).
- Trial name
- NCT03720873
- Testing
- erlotinib or gefitinib or icotinib, Anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Pancreatic Ductal Adenocarcinoma
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
This study adopts a randomized, open label, placebo-controlled, multicenter trial design. OS was the primary endpoint, and eligible subjects were randomly divided into 1:1 groups and received TQB2868 injection and anlotinib…
- Trial name
- NCT07165951
- Testing
- TQB2868 Injection, Anlotinib Hydrochloride Capsules, Gemcitabine Hydrochloride Injection
- Where
- 71 sites in China
- Volunteers
- 566 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Esophageal Cancer (EC)
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
Chemotherapy combined with PD-1 inhibitor immunotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC), yet patient prognosis remains unsatisfactory, with a median PFS of only about 6 months and…
- Trial name
- NCT07863141
- Testing
- anlotinib + PD-1 inhibitor, PD-1 inhibitor
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
To observe the efficacy and safety of hydrochloride anlotinib combined with concurrent radiochemotherapy for patients with FIGO stage IB3 and IIA2-IVA cervical cancer.
- Trial name
- NCT05772377
- Testing
- Hydrochloride anlotinib, cis Platinum/carboplatin, External beam radiotherapy and brachytherapy
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University